Globalisation creates unique regulatory challenges, says CDRH director
This article was originally published in RAJ Devices
Executive Summary
Though the US Food and Drug Administration is increasing the number of foreign inspections it carries out abroad, this is not the only answer to ensuring the safety of imported medical devices, says the director of the agency’s Center for Devices and Radiological Health. During a presentation at AdvaMed’s 2009 International Medical Device Industry Compliance, Regulatory and Intellectual Property Conference held in Rome, Italy, from 25-27 May, Daniel Schultz said that the globalisation of the medtech market had created “unique regulatory challenges” and, thus, the agency needed to find innovative ways to deal with them.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.